Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man

First Posted Date
2014-04-22
Last Posted Date
2014-04-22
Lead Sponsor
Medical University of Vienna
Target Recruit Count
89
Registration Number
NCT02120092
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis

First Posted Date
2014-03-18
Last Posted Date
2016-12-28
Lead Sponsor
Biogen
Target Recruit Count
241
Registration Number
NCT02090413
Locations
🇬🇧

Research Site, Swansea, United Kingdom

Prospective Study Investigating Aspirin and Intraoperative Blood Loss and Complications Following Inguinal Hernia Repair

First Posted Date
2014-03-12
Last Posted Date
2015-06-18
Lead Sponsor
Jesse Brown VA Medical Center
Target Recruit Count
300
Registration Number
NCT02084615
Locations
🇺🇸

Jesse Brown VA Medical Center, Chicago, Illinois, United States

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

First Posted Date
2014-03-07
Last Posted Date
2020-12-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
53
Registration Number
NCT02081638
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

🇺🇸

Hennipen County Medical Center, Minneapolis, Minnesota, United States

A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke

First Posted Date
2014-02-26
Last Posted Date
2018-07-03
Lead Sponsor
Genentech, Inc.
Target Recruit Count
313
Registration Number
NCT02072226
Locations
🇺🇸

Riverside Methodist Hospital, Columbus, Ohio, United States

🇺🇸

University of Arizona, Tucson, Arizona, United States

🇺🇸

Hartford Hospital, Hartford, Connecticut, United States

and more 85 locations

DS1040b/Aspirin Drug/Drug Interaction Study

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-02-25
Last Posted Date
2018-12-24
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
18
Registration Number
NCT02071004
Locations
🇬🇧

Hammersmith Medicines Research Ltd., London, United Kingdom

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

First Posted Date
2014-02-17
Last Posted Date
2017-12-19
Lead Sponsor
Bayer
Target Recruit Count
3365
Registration Number
NCT02064439

Impact of COX2 on Sera Biomarkers From Obese Subjects

Early Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-02-13
Last Posted Date
2016-10-26
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
126
Registration Number
NCT02062255
Locations
🇺🇸

Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States

Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-02-12
Last Posted Date
2014-03-18
Lead Sponsor
Aragon Institute of Health Sciences
Target Recruit Count
24
Registration Number
NCT02060396
Locations
🇪🇸

Hospital clinico Universitario Lozano Blesa, Zaragoza, Spain

Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis

Phase 4
Conditions
Interventions
First Posted Date
2014-02-04
Last Posted Date
2014-02-04
Lead Sponsor
Tunis University
Target Recruit Count
300
Registration Number
NCT02055131
Locations
🇹🇳

clinical and medical investigation in emergency medecine laboratry,hospitalo-university center of Monastir, Monastir, Tunisia

© Copyright 2024. All Rights Reserved by MedPath